- Report
- March 2023
- 10 Pages
Global
From €3035EUR$3,150USD£2,611GBP
- Report
- October 2019
- 103 Pages
Global
€4577EUR$4,750USD£3,937GBP
- Report
- April 2022
- 215 Pages
Global
From €5338EUR$5,540USD£4,592GBP
- Report
- October 2023
- 140 Pages
Global
From €2890EUR$2,999USD£2,486GBP
- Report
- September 2023
- 160 Pages
Global
From €2890EUR$2,999USD£2,486GBP
- Book
- July 2022
- 880 Pages
- Book
- June 2021
- 400 Pages
The Transcatheter Mitral Valve (TMV) is a type of cardiovascular device used to treat mitral valve regurgitation, a condition in which the mitral valve does not close properly, allowing blood to flow backward into the left atrium. TMV is a minimally invasive procedure that involves the insertion of a prosthetic valve into the heart through a catheter. This procedure is an alternative to open-heart surgery, which is more invasive and carries a higher risk of complications.
TMV is a rapidly growing market, with a number of companies developing and marketing products. These companies are focused on improving the safety and efficacy of TMV procedures, as well as expanding the range of patients who can benefit from the procedure. Companies in the TMV market include Edwards Lifesciences, Medtronic, Abbott, Boston Scientific, and Neovasc. Show Less Read more